Tanya Wroblewski Selected Research

Chronic-Phase Myeloid Leukemia (Leukemia, Myeloid, Chronic Phase)

1/2019

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya Wroblewski Research Topics

Disease

1	Bronchiolitis Obliterans Syndrome 07/2020
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019
1	Chronic-Phase Myeloid Leukemia (Leukemia, Myeloid, Chronic Phase) 01/2019
1	Leukemia 01/2019
1	Cardiac Arrhythmias (Arrythmia) 12/2018
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 11/2017
1	Sarcoma (Soft Tissue Sarcoma) 04/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2008

Drug/Important Bio-Agent (IBA)

3	ibrutinibIBA 07/2020 - 11/2017
1	nilotinib FDA Link 01/2019

Therapy/Procedure

1	Therapeutics 07/2020
1	Drug Therapy (Chemotherapy) 04/2008